Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Strategic Maneuvers | Explore Pfizer's bold $1.25 billion acquisition of SSGJ-707, a VEGFxPD-1 bispecific antibody, signaling its commitment to oncology expansion |
Financial Resilience | Delve into Pfizer's robust financial performance, with 2024 revenues reaching $63.6 billion and EPS exceeding expectations at $3.11 |
Pipeline Potential | Discover ponsegromab, Pfizer's promising GDF-15 inhibitor for cancer cachexia, representing a multi-billion dollar opportunity in an untapped market |
Market Outlook | Analyst price targets range from $24 to $45, reflecting varied perspectives on Pfizer's growth potential amid upcoming patent expirations and strategic initiatives |
Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
---|---|---|---|---|
P/E Ratio | 17.4x | −1.1x | −0.5x | |
PEG Ratio | 0.01 | −0.02 | 0.00 | |
Price/Book | 1.5x | 2.6x | 2.6x | |
Price / LTM Sales | 2.2x | 7.1x | 3.0x | |
Upside (Analyst Target) | 17.3% | 195.6% | 52.5% | |
Fair Value Upside | Unlock | 5.5% | 8.7% | Unlock |